CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I.
Schernthaner G, et al.
Diabetes Res Clin Pract. 2019 Jul;153:30-40. doi: 10.1016/j.diabres.2019.05.013. Epub 2019 May 20.
Diabetes Res Clin Pract. 2019.
PMID: 31121272
Free article.
To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group of diabetes specialists from the Central and Eastern Europe region to discuss the new disclosures. ...Here, we noted the clinical relevance t …
To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group o …